Business
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n- Data demonstrated strong correlation between LymPro and amyloid PET- Todos to present at Alzheimer’s Solutions Conference on June 3, 2019 in Philadelphia- Todos to present at LD Micro on June 4th, 2019\n REHOVOT, Israel, May 28, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it has received and analyzed data from the University of Leipzig on the lymphocyte proliferation test (‘LymPro”), which demonstrated a strong correlation between LymPro and amyloid PET. Upon review of the LymPro data, Todos Medical exercised its exclusive option to acquire the remaining 80.01% of its joint venture Breakthrough Diagnostics from Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS). The transaction is expected to close upon listing of Todos’ common stock on a national stock exchange. “Todos Medical was very pleased with the positive data we received from the University of Leipzig on the LymPro test,” said Herman Weiss, MD, President & CEO of Todos Medical. “The data we received is exciting as we believe it will lead to the creation of a screening test for Alzheimer’s disease, potentially the first to be developed. With LymPro’s focus on measuring immune markers that are directly linked to well established cell proliferation processes, we are expanding our understanding of how the body’s immune system responds to disease and how we can use this response to diagnose early and monitor the progression of Alzheimer’s disease. We believe this could be an invaluable tool for pharmaceutical companies’ development of novel treatments for Alzheimer’s, as well as a critical component to early diagnosis that may have a meaningful impact on the cost-curve associated with Alzheimer’s, estimated to be currently $250 billion annually in the US, and expected to grow to $1.2 trillion by 2050.”   “Todos Medical is rapidly building upon its deep understanding of the interplay between immune system and aberrant cell proliferation processes that lead to disease,” said Gerald E. Commissiong, President & CEO of Amarantus and Inter...